Cancers and NASH

Patients and physicians have to know that NASH increases the risk to develop cancers. Specific surveillance has to be implemented when indicated. Hepatocellular carcinoma is rare in patients with NASH without advanced fibrosis, but seems to occur not rarely when the liver is not yet cirrhotic. Some molecular mechanisms seem specific to NASH-related HCC. The management is similar to HCC with other underlying liver disease. Patients with NASH-related HCC may respond less to immuno-oncology.